Compared to the surrounding non-malignant tissues, the protein and mRNA levels of CYLD in HCC are both lower, and it is believed that downregulating CYLD in HCC cell lines increases the resistance of HCC cells to treatment with doxorubicin, 5-fluorouracil, and cisplatin. The gene discussed is CYLD; the disease is hepatocellular carcinoma.